We are delighted to announce that ONCOassist is now CE approved. After months of hard work we are glad to say that ONCOassist is proudly labelled with a CE mark. We are the 1st Irish and 3rd company worldwide to be granted a CE mark for a smartphone app.
What does this mean?
ONCOassist is now classified as a “medical device” and can be used in a hospital to make clinical decisions. All other clinical decision support apps on the market should not be used in a hospital setting and would not pass hospital procurement standards. We are fully compliant with EU regulations for clinical decision support tools.
Why does ONCOassist need CE approval?
ONCOassist allows oncologists to make complex decisions regarding chemotherapy, steroids and opioid dosages and therefore needs CE and FDA approval. Doctors can input patient specific information and get output of how much they should prescribe their patients.
We strongly believe that apps used to make clinical decisions need to go through the appropriate CE and FDA standards before being used in a clinical setting. A recent study by the Journal of Telemedicine and Telecare found no expert involvement in 86% of apps developed for pain management. We want to change this, we are in the process of developing a series of “assist” apps that will aid clinicians with their day-to-day clinical decision making.
More about ONCOassist
Currently released for the iPhone and iPad, ONCOassist combines key clinical tools, guidelines and information to aid oncologists in their point of care decision making. The information on ONCOassist has been vetted and developed in conjunction with Co-Founder Dr Richard Bambury a specialist registrar in medical oncology and therefore is safe to be used in clinical decision making.
You can download ONCOassist here : – https://itunes.apple.com/us/app/oncoassist/id558299114
If you have any queries about the above please feel free to contact us.